Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Imatinib in Intermediate-risk GIST with High Genomic Grade Index
NCT02576080Phase 3Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Oct 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Rate of metastatic relapse at 2 years. Status: unknown.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02576080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576080.